About Olympus (OTCMKTS:OCPNY)
Olympus Corporation is engaged in the manufacture and sale of precision machineries and instruments. The Company's segments include Medical Business, Scientific Solutions Business, Imaging Business and Others. The Company's Medical Business manufactures and sells medical endoscopes, surgical endoscopes, endotherapy devices and other products. Its Scientific Solutions Business manufactures and sells biological microscopes, industrial microscopes, industrial endoscopes, non-destructive testing equipment and other products. Its Imaging Business manufactures and sells digital cameras, voice recorders and other products. Its Others Business manufactures and sells biomedical materials, conducts system development and other business activities. Its technologies include optical technologies, electronic imaging technologies, precision technologies and biological based technologies. It has a service network consisting of over 200 sites on approximately six continents.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E Ratio23.68
Forward P/E Ratio22.22
Sales & Book Value
Annual Sales$6.92 billion
Price / Sales1.85
Cash Flow$2.97 per share
Price / Cash12.58
Book Value$11.69 per share
Price / Book3.19
Net Income$727.17 million
Return on Equity14.43%
Return on Assets6.23%
Olympus (OTCMKTS:OCPNY) Frequently Asked Questions
What is Olympus' stock symbol?
Olympus trades on the OTCMKTS under the ticker symbol "OCPNY."
How were Olympus' earnings last quarter?
Olympus Corp (OTCMKTS:OCPNY) posted its earnings results on Friday, February, 9th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.12. The company had revenue of $1.80 billion for the quarter, compared to analyst estimates of $1.75 billion. Olympus had a net margin of 10.78% and a return on equity of 14.43%. View Olympus' Earnings History.
When will Olympus make its next earnings announcement?
Who are some of Olympus' key competitors?
Some companies that are related to Olympus include Zimmer Biomet (ZBH), Sunny Optical Tech (SNPTF), Align Technology (ALGN), Cardinal Health (CAH), AmerisourceBergen (ABC), Lonza Group (LZAGY), IDEXX Laboratories (IDXX), Laboratory Corp. of America (LH), Smith & Nephew (SNN), Coloplast A/S (CLPBY), ResMed (RMD), ABIOMED (ABMD), DENTSPLY SIRONA (XRAY), Teleflex (TFX), Perrigo (PRGO), Varian Medical Systems (VAR), Cooper Companies (COO) and Hologic (HOLX).
Who are Olympus' key executives?
Olympus' management team includes the folowing people:
- Hiroyuki Sasa, Executive President, Representative Director (Age 61)
- Yasuo Takeuchi, Chief Financial Officer, Executive Vice President, Chairman of Subsidiary, Director (Age 60)
- Haruo Ogawa, Chief Technology Officer, Senior Managing Executive Officer, Manager of Technology Development, Director (Age 60)
- Kiichi Hirata, Chief Administrative Officer, Managing Executive Officer, Director (Age 60)
- Akihiro Taguchi, Senior Managing Executive Officer, Manager of Sales & Marketing, Director (Age 59)
- Shigeo Hayashi, Senior Managing Executive Officer, Manager of Manufacturing (Age 59)
- Nobuhiro Abe, Managing Executive Officer
- Naohiko Kawamata, Managing Executive Officer, Chief Director of Procurement
- Yasushi Sakai, Managing Executive Officer, Chief Improvement Officer
- Toshihiko Ohkubo, Executive Officer, Chief Director of Scientific Marketing, Manager of Scientific Business Unit
Has Olympus been receiving favorable news coverage?
News stories about OCPNY stock have been trending somewhat negative this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Olympus earned a news sentiment score of -0.07 on Accern's scale. They also gave news articles about the company an impact score of 45.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Olympus?
Shares of OCPNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Olympus' stock price today?
One share of OCPNY stock can currently be purchased for approximately $37.33.
How big of a company is Olympus?
Olympus has a market capitalization of $13.06 billion and generates $6.92 billion in revenue each year. The company earns $727.17 million in net income (profit) each year or $2.20 on an earnings per share basis.
How can I contact Olympus?
Olympus' mailing address is SHINJUKU MONOLITH 3-1 NISHI-SHINJUKU 2-CHOME, SHINJUKU-KU TOKYO M0, 163-0914. The company can be reached via phone at 813-3340-2427 or via email at [email protected]
MarketBeat Community Rating for Olympus (OCPNY)MarketBeat's community ratings are surveys of what our community members think about Olympus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Olympus (OTCMKTS:OCPNY) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Olympus (OTCMKTS:OCPNY) Earnings History and Estimates Chart
Olympus (OTCMKTS OCPNY) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2018|| || || || || || || || |
|2/9/2018||Q3 2018||$0.35||$0.47||$1.75 billion||$1.80 billion||View||N/A|
|11/8/2017||Q2 2018||$0.52||$1.57 billion||$1.78 billion||View||N/A|
|8/8/2017||Q1 2018||$0.26||$1.55 billion||View||N/A|
|5/2/2017||Q4 2017||$1.00||$0.36||$1.90 billion||$1.89 billion||View||N/A|
|2/2/2017||Q3 2017||$0.53||$1.66 billion||$1.68 billion||View||N/A|
|11/2/2016||Q2 2017||$0.44||$1.95 billion||$1.77 billion||View||N/A|
|8/3/2016||Q1 2017||$0.23||$1.69 billion||$1.56 billion||View||N/A|
|5/5/2016||Q3 2016||$0.57||$1.61 billion||View||N/A|
|11/6/2015||Q2 2016||$0.50||$1.71 billion||View||N/A|
|8/6/2015||Q1 2016||$0.40||$1.54 billion||View||N/A|
|5/8/2015||Q4 2015||$0.39||$1.80 billion||View||N/A|
|2/6/2015||Q3 2015||$0.38||$1.66 billion||View||N/A|
|11/7/2014||Q2 2015||$0.40||$1.64 billion||View||N/A|
|8/7/2014||Q1 2015||$0.23||$1.64 billion||View||N/A|
|5/9/2014||Q4 2014||$0.69||$1.96 billion||View||N/A|
|11/8/2013||Q2 2014||$0.44||$1.76 billion||View||N/A|
|8/8/2013||Q1 2014||($0.03)||$1.64 billion||View||N/A|
|5/15/2013||Q4 2013||($0.15)||$1.78 billion||View||N/A|
Olympus (OTCMKTS:OCPNY) Earnings Estimates
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Olympus (OTCMKTS:OCPNY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Olympus (OTCMKTS OCPNY)
No insider trades for this company have been tracked by MarketBeat.com
Olympus (OTCMKTS OCPNY) News Headlines
|Olympus (OCPNY) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - February 24 at 7:10 AM
|Judge orders new superbug trial after finding that Olympus didn't properly disclose safety concerns|
www.latimes.com - January 18 at 8:34 PM
|Research Analysts Issue Forecasts for Olympus Corp's Q3 2018 Earnings (OCPNY)|
www.americanbankingnews.com - January 15 at 7:40 AM
|ETFs with exposure to Olympus Corp. : December 27, 2017|
finance.yahoo.com - December 27 at 2:37 PM
|Zacks Investment Research Downgrades Olympus (OCPNY) to Hold|
www.americanbankingnews.com - December 17 at 10:38 AM
|Olympus Corp. :OCPNY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 12, 2017|
finance.yahoo.com - December 12 at 10:40 AM
|Short-Sale Portfolio Made of Japan's Corporate Cheats|
finance.yahoo.com - November 30 at 4:38 PM
|Japan's List of Corporate Corner-Cutters Might Make for a Short-Sale Portfolio|
finance.yahoo.com - November 30 at 10:51 AM
|Olympus Corp. (OCPNY) Raised to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - November 24 at 2:02 PM
|FY2018 EPS Estimates for Olympus Corp. (OCPNY) Increased by Analyst|
www.americanbankingnews.com - November 18 at 9:36 AM
|Olympus Corp. (OCPNY) Downgraded to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - November 11 at 7:16 AM
|ETFs with exposure to Olympus Corp. : October 27, 2017|
finance.yahoo.com - October 28 at 10:47 AM
|ETFs with exposure to Olympus Corp. : October 17, 2017|
finance.yahoo.com - October 18 at 7:55 AM
|Olympus Corp. (OCPNY) Cut to Strong Sell at Zacks Investment Research|
www.americanbankingnews.com - October 16 at 12:14 AM
|ETFs with exposure to Olympus Corp. : October 4, 2017|
finance.yahoo.com - October 5 at 1:34 PM
|Olympus Corp. :OCPNY-US: Earnings Analysis: Q1, 2018 By the Numbers : October 2, 2017|
finance.yahoo.com - October 2 at 7:40 PM
|ETFs with exposure to Olympus Corp. : August 4, 2017|
finance.yahoo.com - August 5 at 5:15 AM
|Jury orders Olympus to pay $6.6 million but rejects claims its medical scopes are unsafe|
www.latimes.com - July 25 at 8:17 AM
|ETFs with exposure to Olympus Corp. : July 12, 2017|
finance.yahoo.com - July 13 at 7:32 AM
|Olympus Corp. :OCPNY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 11, 2017|
finance.yahoo.com - July 12 at 6:33 AM
|Olympus executives plead the 5th when questioned about the deadly outbreaks tied to the company's medical scopes|
www.latimes.com - December 19 at 10:04 AM
|Boston Scientific Unveils Improved Endoclip (BSX)|
www.investopedia.com - October 19 at 11:38 AM
|Congressman calls on Japanese prosecutors to probe Olympus over scope infections|
www.latimes.com - September 1 at 6:52 PM
|[video]Olympus Teams Up With Sony for Surgical Big Screen TV|
www.thestreet.com - April 9 at 10:26 PM
|Olympus sought price hike for UCLA amid superbug outbreak|
www.latimes.com - March 25 at 6:04 AM
|Whistleblower Delivers A Triple Whammy To Olympus; More Companies Might Get Hit|
www.forbes.com - March 4 at 5:45 PM
|Olympus to pay at least $635 million to settle kickback and bribery cases|
www.latimes.com - March 1 at 2:20 PM
|Olympus Will Pay $646 Million to End Kickback, Bribe Probes|
www.bloomberg.com - March 1 at 10:27 AM
|FDA Approves Fixes for Olympus Scope Linked to Infections|
www.wsj.com - January 17 at 7:57 PM
|Olympus to recall and redesign medical scope linked to superbug outbreaks|
www.latimes.com - January 15 at 1:04 PM
|Ex-Olympus CEO Woodford Sues Company for Breach of Contract|
www.bloomberg.com - January 15 at 12:59 PM
|Congressman wants SEC probe into Olympus over superbug outbreak|
www.bizjournals.com - December 23 at 4:00 PM
Olympus (OTCMKTS:OCPNY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Olympus (OTCMKTS OCPNY) Stock Chart for Friday, March, 23, 2018